Objective: Chemical neurolysis of the genicular nerves is a treatment option for intractable non-cancer knee pain. This scoping review synthesizes the available literature on the effectiveness, adverse events, and procedural techniques of chemical neurolysis of genicular nerves for the management of knee pain.

Design: Scoping review.

Setting: All clinical and research settings.

Subjects: Adult participants with chronic non-cancer knee pain undergoing chemical neurolysis of genicular nerves.

Methods: A literature search in MEDLINE, EMBASE, and Cochrane Library was conducted up to September 4, 2023. Articles were searched via terms and keywords relating to "knee," "pain," "knee osteoarthritis," "ablation," "alcohol," "phenol," and "chemical neurolysis." Included articles were full-text primary studies and in English. Data were extracted by 2 independent reviewers using an electronic database.

Results: Eight studies were included in this review (including 1 randomized controlled trial), comprising 192 patients. Of the 8 studies, 4 used phenol, 3 used alcohol, and 1 used either alcohol or phenol for chemical neurolysis. Fluoroscopy, ultrasound guidance, or both were used for nerve target identification. All studies demonstrated that chemical neurolysis resulted in improved pain or functional outcomes, with no serious adverse events reported.

Conclusions: Chemical neurolysis of the genicular nerves is a promising treatment strategy for chronic knee pain. Interpretation of the available studies is limited by study heterogeneity and small sample sizes. High-quality randomized controlled trials are required to clarify the selection of appropriate nerve targets and choice of image guidance and to compare with other ablative modalities.

Study registration: Open Science Framework (https://osf.io/jg8wh).